Iterum Therapeutics reports 2022 net loss $44.4M; cash $60.8M funds to mid-2024

Iterum Therapeutics plc

Cash, cash equivalents and short-term investments $60.8M; expected to fund operations until mid-2024.
Net loss Q4 2022 $5.1M, full year $44.4M; non-GAAP net loss $6.4M and $22.9M respectively.
REASSURE trial enrollment ongoing, expected completion H1 2024; interim analysis at 50% enrollment H2 2023.
Two new US patents issued for oral sulopenem (composition and method of use), expiring no earlier than 2039.
Shareholder class action lawsuit dismissed with prejudice on January 25, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Iterum Therapeutics plc reported fourth quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l.

Period: fourth quarter and year ended December 31, 2022
Net income: Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l
Result: reported results

Exact text from the filing

Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-23-008293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.